BMS Makes The Case For A Lasting Hematology Legacy
ASH Meeting Will Highlight Key Growth Products
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
You may also be interested in...
BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.
Bristol’s Growth Plan Faces First Test In 2022
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.
Could CD47 Competitors Catch Up To Gilead After Magrolimab Hold?
Gilead isn’t giving details about the events behind the partial hold on magrolimab/Vidaza combination studies, but analysts suspect cytopenias are the culprit.